See more than ever before

The world’s most sensitive liquid biopsy minimal residual disease (MRD) test that detects the earliest hints of cancer relapse.

Lymphoma assay extensively validated in hundreds of patients with B-cell malignancies
Detect relapse 200+ days earlier By detecting 1 part per million
See what others miss

Latest Updates

May 02, 2022

Jake Chabon Ph.D., Co-founder/CEO of Foresight Diagnostics joins the Berkeley Center for Law & Technology (BCLT) Expert Series podcast

Apr 26, 2022

Foresight Diagnostics Expands Scientific Advisory Board with Appointment of Christopher R. Flowers, M.D., M.S.

Apr 06, 2022

Phase 2 Study of Acalabrutinib Window Prior to Frontline Therapy in Untreated Aggressive B-cell Lymphoma

icon-download Download Poster